2 Once the procedure became widespread, the Wallstent self-expandable stent (Boston Scientific, Natick, MS) became the preferred stent because of its flexibility, range of lengths and diameters, and ease of use.
Both the balloon-expandable iCast and the self-expandingViabahn have an important role in treating occlusiveiliac artery disease. Balloon-expandable stents have classicallybeen the therapy of choice for aortoiliac bifurcationdisease, but evolving data suggest that the iCast could be asuitable alternative. The iCARUS trial will further definethe role of stent grafts in aortoiliac occlusive disease. TheViabahn endoprosthesis is the only currently availableFDA-approved covered stent for the iliac artery and is aviable alternative to self-expanding nitinol stents in theexternal iliac vessel. Future trials will provide additionaldata on appropriate patient selection, as well as the safetyand efficacy of these devices.
Thox WALLSTENT Endoprosthesis Boston Scientific
AB - PURPOSE: To evaluate the efficacy of the Wallstent endoprosthesis for treatment of stenotic or occlusive inferior vena cava (IVC) lesions refractory to balloon angioplasty in patients after orthotopic liver transplantation. MATERIALS AND METHODS: Wallstent endoprostheses were implanted in six patients with IVC anastomotic stenoses or occlusions that were refractory to balloon angioplasty. Follow-up included both duplex ultrasound (US) and clinical evaluations. RESULTS: Ten stents were successfully implanted in six patients. Five of six patients (83%) demonstrated primary patency on duplex US for a mean period of 11 months (range, 4-17 months). One patient's symptoms recurred within 3 weeks after intervention. This patient underwent repeated stent placement. Follow-up duplex US in this patient demonstrated primary assisted patency at 7 months. Mean clinical follow-up was 12 months (range, 7-18 months). Other than the previously described case, no patient developed recurrent symptoms of IVC stenosis or occlusion. Two patients who experienced hemorrhagic complications secondary to anticoagulation were treated successfully. CONCLUSIONS: The Wallstent endoprosthesis is a useful adjunct for treatment of IVC stenosis or occlusions in patients who have undergone orthotopic liver transplantation when these lesions are refractory to simple balloon angioplasty.
Boston Scientific’s Postapproval CABANA Study of …
In an analysis of 168 limbs with venous stasis ulcers, there was no difference in ulcer healing with stent correction alone between limbs that had axial reflux and those without (). Limbs with a reflux segment score ≥ 3 appeared to have a lower rate of healing (P This experience raises fundamental questions regarding the relative importance of obstruction versus reflux in ulcer pathology.The iliac vein stent experience outlined previously is with off-label use of a Wallstent endoprosthesis (Boston Scientific Corporation), which is designed for extravascular use.
Abbott Vascular | Xpert Self-Expanding Stent System
We performed a prospective randomized study to compare the use of a bare metal stent (WALLSTENTEndoprosthesis) with use of a covered stent (WALLGRAFT E...
Abbott Vascular Xpert Self-Expanding Stent System ..
Boston Scientific advised that the carotid Wallstent Monorail endoprosthesis is a self-expanding stent with a closed-cell design, which provides increased scaffolding for improved lesion coverage and a smooth inner lumen. The device features a highly flexible, low-profile stent delivery system that is designed to track through difficult anatomy. The FilterWire EZ embolic protection system is designed to capture plaque debris that may be released during a procedure. The US Food and Drug Administration approved the device in 2008, and it is available in all major markets worldwide. The FilterWire EZ received US Food and Drug Administration clearance for use in carotid artery stenting procedures in 2006.